Unknown

Dataset Information

0

Restoration of miR-23a expression by chidamide sensitizes CML cells to imatinib treatment with concomitant downregulation of CRYAB.


ABSTRACT: MicroRNAs (miRNAs) are involved in various processes from the initiation and development of cancers, including chronic myeloid leukemia (CML). In this report, we aimed to investigate the roles of miR-23a in the regulation of imatinib mesylate (IM) sensitivity in CML cells and the possible mechanisms involved in this process. We demonstrated that the expression of miR-23a was markedly low in bone marrow mononuclear cells from patients in whom IM treatment had failed and imatinib-resistant K562/G01 cells when compared to patients with optimal responses and imatinib-sensitive K562 cells, respectively. Overexpression of miR-23a was shown to induce apoptosis of K562/G01 cells and sensitize these cells to imatinib treatment. With the aid of bioinformatics analysis, we revealed that CRYAB could be a potential downstream effector of miR-23a, contributing to miR-23a-mediated IM resistance. We also observed that the expression of CRYAB was inversely correlated with miR-23a expression in CML cell lines and patient samples. Importantly, chidamide upregulated miR-23a expression and reversed the IM resistance of CML cells. Together, these findings strongly suggest that miR-23a acts as a tumor suppressor by downregulating CRYAB expression. Restoration of miR-23a by chidamide may therefore have a therapeutic effect in controlling the sensitivity of CML cells to imatinib.

SUBMITTER: Zhu X 

PROVIDER: S-EPMC9162009 | biostudies-literature | 2022 Apr

REPOSITORIES: biostudies-literature

altmetric image

Publications

Restoration of miR-23a expression by chidamide sensitizes CML cells to imatinib treatment with concomitant downregulation of CRYAB.

Zhu Xunxun X   Zhang Jingru J   Sun Yanping Y   Wang Yan Y   Liu Qian Q   Li Peng P   Yu Shuang S   Liu Na N   Ye Jingjing J   Ma Daoxin D   Ji Chunyan C  

Bioengineered 20220401 4


MicroRNAs (miRNAs) are involved in various processes from the initiation and development of cancers, including chronic myeloid leukemia (CML). In this report, we aimed to investigate the roles of miR-23a in the regulation of imatinib mesylate (IM) sensitivity in CML cells and the possible mechanisms involved in this process. We demonstrated that the expression of miR-23a was markedly low in bone marrow mononuclear cells from patients in whom IM treatment had failed and imatinib-resistant K562/G0  ...[more]

Similar Datasets

| S-EPMC4695064 | biostudies-literature
| S-EPMC6072189 | biostudies-literature
| S-EPMC9208477 | biostudies-literature
| S-EPMC4849026 | biostudies-literature
| S-EPMC4107397 | biostudies-literature
| S-EPMC6969434 | biostudies-literature
| S-EPMC5056971 | biostudies-literature
| S-EPMC7055176 | biostudies-literature
| S-EPMC4038039 | biostudies-literature
| S-EPMC4615800 | biostudies-other